张磊砢

1）利用经典病毒学、生物化学等手段研究复制相关病毒关键蛋白的作用机制，发展靶向其小分子抑制剂

2）利用系统生物学等手段研究病毒与宿主互作，发展靶向病毒复制依赖宿主因子的小分子抑制剂

教育及工作经历

1.核转运蛋白参与沙粒病毒出芽过程的机制研究；国家自然科学基金委面上项目；2020-01到2023-12；主持

2.新发突发病毒复制蛋白机器与广谱药物靶点研究；国家重点研发计划项目；2021-12到2024-11；课题负责人

3.一种广谱抗沙粒病毒、布尼亚病毒药物的机制研究；中国科学院任务；2018-06到2021-06；主持

4.中科院青年创新促进会；中国科学院任务；2018-01到2021-12；主持

5.一类氰基化合物、其制备方法及用途；企业委托；2021-06到2026-12；主持

1.Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, Li C, Li Y, Bai F, Wang H, Cheng X, Cen X, Hu S, Yang X, Wang J, Liu X, Xiao G, Jiang H, Rao Z, Zhang LK, Xu Y, Yang H, Liu H. 2020. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368:1331-1335. (共通讯)

2.Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, Tian G, Aisa HA, Xu Y, Xiao G, Li J, Jiang H, Zhang S, Zhang L, Xu HE, Shen J. 2021. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. (共通讯)

3.Li H, Zhang LK, Li SF, Zhang SF, Wan WW, Zhang YL, Xin QL, Dai K, Hu YY, Wang ZB, Zhu XT, Fang YJ, Cui N, Zhang PH, Yuan C, Lu QB, Bai JY, Deng F, Xiao GF, Liu W, Peng K. 2019. Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Cell Res 29:739-753. (共第一)

4.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269-271. (共第一)

5.Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, Duan Y, Yu J, Yang X, Yang X, Yang K, Liu X, Guddat LW, Xiao G, Zhang L, Yang H, Rao Z. 2020. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nature structural & molecular biology 27:529-532. (共通讯)

6.Yin W, Luan X, Li Z, Zhou Z, Wang Q, Gao M, Wang X, Zhou F, Shi J, You E, Liu M, Wang Q, Jiang Y, Jiang H, Xiao G, Zhang L, Yu X, Zhang S, Eric Xu H. 2021. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nature structural & molecular biology 28:319-325. (共通讯)

7.Su H, Yao S, Zhao W, Zhang Y, Liu J, Shao Q, Wang Q, Li M, Xie H, Shang W, Ke C, Feng L, Jiang X, Shen J, Xiao G, Jiang H, Zhang L, Ye Y, Xu Y. 2021. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nature communications 12:3623. (共通讯)

8.Amporndanai K, Meng X, Shang W, Jin Z, Rogers M, Zhao Y, Rao Z, Liu ZJ, Yang H, Zhang L, O'Neill PM, Samar Hasnain S. 2021. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nature communications 12:3061. (共通讯)

9.Li S, Li H, Zhang YL, Xin QL, Guan ZQ, Chen X, Zhang XA, Li XK, Xiao GF, Lozach PY, Cui J, Liu W, Zhang LK, Peng K. 2020. SFTSV Infection Induces BAK/BAX-Dependent Mitochondrial DNA Release to Trigger NLRP3 Inflammasome Activation. Cell reports 30:4370-4385 e4377. (共通讯)

10.Wu J, Shi Y, Pan X, Wu S, Hou R, Zhang Y, Zhong T, Tang H, Du W, Wang L, Wo J, Mu J, Qiu Y, Yang K, Zhang LK, Ye BC, Qi N. 2021. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell reports 34:108761. (共通讯)

11.Zhang LK, Sun Y, Zeng H, Wang Q, Jiang X, Shang WJ, Wu Y, Li S, Zhang YL, Hao ZN, Chen H, Jin R, Liu W, Li H, Peng K, Xiao G. 2020. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov 6:96.

12.Zhao Y, Du X, Duan Y, Pan X, Sun Y, You T, Han L, Jin Z, Shang W, Yu J, Guo H, Liu Q, Wu Y, Peng C, Wang J, Zhu C, Yang X, Yang K, Lei Y, Guddat LW, Xu W, Xiao G, Sun L, Zhang L, Rao Z, Yang H. 2021. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein & cell. (共通讯)

13.Li H, Jiang XM, Cui N, Yuan C, Zhang SF, Lu QB, Yang ZD, Xin QL, Song YB, Zhang XA, Liu HZ, Du J, Fan XJ, Yuan L, Yuan YM, Wang Z, Wang J, Zhang L, Zhang DN, Wang ZB, Dai K, Bai JY, Hao ZN, Fan H, Fang LQ, Xiao G, Yang Y, Peng K, Wang HQ, Li JX, Zhang LK, Liu W. 2021. Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome. Signal transduction and targeted therapy 6:145. (共通讯)

14.Zhu S, Wan W, Zhang Y, Shang W, Pan X, Zhang LK, Xiao G. 2019. Comprehensive Interactome Analysis Reveals that STT3B is Required for the N-Glycosylation of Lassa Virus Glycoprotein. J Virol. (共通讯)

15.Zhang LK, Wang B, Xin Q, Shang W, Shen S, Xiao G, Deng F, Wang H, Hu Z, Wang M. 2019. Quantitative Proteomic Analysis Reveals Unfolded-Protein Response Involved in Severe Fever with Thrombocytopenia Syndrome Virus Infection. J Virol 93.

16.Zhang LK, Xin QL, Zhu SL, Wan WW, Wang W, Xiao G. 2016. Activation of the RLR/MAVS Signaling Pathway by the L Protein of Mopeia Virus. J Virol 90:10259-10270.

17.Xin QL, Deng CL, Chen X, Wang J, Wang SB, Wang W, Deng F, Zhang B, Xiao G, Zhang LK. 2017. Quantitative Proteomic Analysis of Mosquito C6/36 Cells Reveals Host Proteins Involved in Zika Virus Infection. J Virol 91.

18.Wan W, Zhu S, Li S, Shang W, Zhang R, Li H, Liu W, Xiao G, Peng K, Zhang L. 2021. High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2. ACS infectious diseases 7:1409-1422.